Table 1

Effect of SGLT2i in NAFLD

Author, year	Agent	n	Duration (weeks)	Comparator	Main study results
Author, year	Agent	n	Duration (weeks)	Comparator	Body weight^*	ALT	Liver fat^*
Prospective open-label studies
Ito et al., 2017 (42)	Ipragliflozin	66	24	Pioglitazone	↓ 3.7%	↓	↓^¶
Ohta et al., 2017 (43)	Ipragliflozin	20	24	Standard care	↓ 2.5%	↓	↓ 39%
Shibuya et al., 2018 (44)	Luseogliflozin	32	24	Standard care	↓ 3.2%	Unchanged	↓^¶
Kuchay et al., 2018 (45)	Empagliflozin	50	20	Standard care	↓ 1.1%	↓	↓ 26%
Shimizu et al., 2019 (46)	Dapagliflozin	57	24	Standard care	↓ 3.1%	↓	↓^†
Inoue et al., 2019 (47)	Canagliflozin	20	52	Standard care	↓ 3.4%	↓	↓ 31%
Randomized controlled trials
Bolinder et al., 2012 (48)	Dapagliflozin	67	24	Placebo	↓ 2.2%	—	Unchanged
Eriksson et al., 2018 (49)	Dapagliflozin	84	12	Placebo	↓ 2.2%	↓	↓ 10%^§
Cusi et al., 2019 (50)	Canagliflozin	56	24	Placebo	↓ 3.4%	Unchanged	↓ 18%^§
Latva-Rasku et al., 2019 (51)	Dapagliflozin	32	8	Placebo	↓ 2.1%	Unchanged	↓ 13%
Kahl et al., 2019 (52)	Empagliflozin	84	24	Placebo	↓ 2.4%	Unchanged	↓ 22%

Arrows indicate statistically significant changes vs. comparator.
↵* Comparison-corrected (open-label) or placebo-corrected relative treatment difference in weight and liver fat measured with MRI-based imaging techniques.
↵¶ Liver fat measured as liver-to-spleen attenuation ratio on computed tomography. In Ito et al. (42) the decrease in liver fat was similar to pioglitazone (comparator).
↵† Significant improvement in liver fat by controlled attenuation parameter (CAP; Fibroscan).
↵§ Not significant compared with placebo.